Title |
Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer
|
---|---|
Published in |
Journal of Hematology & Oncology, April 2016
|
DOI | 10.1186/s13045-016-0268-z |
Pubmed ID | |
Authors |
Shuhang Wang, Shundong Cang, Delong Liu |
Abstract |
The tyrosine kinase inhibitors (TKI) against epidermal growth factor receptor (EGFR) are widely used in patients with non-small cell lung cancer (NSCLC). However, EGFR T790M mutation leads to resistance to most clinically available EGFR TKIs. Third-generation EGFR TKIs against the T790M mutation have been in active clinical development. These agents include osimertinib, rociletinib, HM61713, ASP8273, EGF816, and PF-06747775. Osimertinib and rociletinib have shown clinical efficacy in phase I/II trials in patients who had acquired resistance to first- or second-generation TKIs. Osimertinib (AZD9291, TAGRISSO) was recently approved by FDA for metastatic EGFR T790M mutation-positive NSCLC. HM61713, ASP8237, EGF816, and PF-06747775 are still in early clinical development. This article reviews the emerging data regarding third-generation agents against EGFR T790M mutation in the treatment of patients with advanced NSCLC. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 1 | 20% |
United States | 1 | 20% |
Unknown | 3 | 60% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 4 | 80% |
Science communicators (journalists, bloggers, editors) | 1 | 20% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 1 | <1% |
Brazil | 1 | <1% |
Unknown | 227 | 99% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 38 | 17% |
Researcher | 37 | 16% |
Student > Bachelor | 34 | 15% |
Student > Master | 21 | 9% |
Other | 16 | 7% |
Other | 38 | 17% |
Unknown | 45 | 20% |
Readers by discipline | Count | As % |
---|---|---|
Biochemistry, Genetics and Molecular Biology | 51 | 22% |
Medicine and Dentistry | 45 | 20% |
Agricultural and Biological Sciences | 25 | 11% |
Pharmacology, Toxicology and Pharmaceutical Science | 22 | 10% |
Chemistry | 17 | 7% |
Other | 15 | 7% |
Unknown | 54 | 24% |